P. H. Warne

Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation.

J. Downward, M. Waterfield, B. Vanhaesebroeck, 1996, The EMBO journal.

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

B. Weigelt, J. Downward, P. Warne, 2011, Oncogene.

Murine Ksr interacts with MEK and inhibits Ras-induced transformation

J. Downward, A. Eychène, G. Calothy, 1998, Current Biology.

Rictor is a novel target of p70 S6 kinase-1

J. Downward, M. Magnuson, C. Treins, 2010, Oncogene.

Role of Shc in the activation of Ras in response to epidermal growth factor and nerve growth factor.

J. Downward, T. Basu, P. H. Warne, 1994, Oncogene.

Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos.

J. Downward, L. Buday, P. H. Warne, 1995, Oncogene.

Networks of interaction of p120cbl and p130cas with Crk and Grb2 adaptor proteins.

J. Downward, A. Khwaja, B. Hallberg, 1996, Oncogene.

Phosphatidylinositol 3' kinase: one of the effectors of Ras.

P. Warne, J. Downward, P. Rodriguez-Viciana, 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.